Extracorporeal Membrane Oxygenation Complication
76
20
22
25
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
2.6%
2 terminated out of 76 trials
92.6%
+6.1% vs benchmark
8%
6 trials in Phase 3/4
12%
3 of 25 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 25 completed trials
Clinical Trials (76)
Platform of Randomized Adaptive Clinical Trials in Critical Illness
The ECMO-Free Trial
"Continuous Positive Airway Pressure on Venovenous extracorporeaL Membrane Oxygenation for Acute respIratory Distress syndrOme"
Safety and Performance of the Novalung Ultimate Kit and Xenios 2.0 During Stationary Use in Hospital and Ground-based Transport of Patients on Extracorporeal Life Support (ECLS)
Study on the Efficacy and Timing of ECMO Therapy in Children With Refractory Septic Shock
Anticoagulation-free VV ECMO for Acute Respiratory Failure
Low-Field Bedside Brain Magnetic Resonance Imaging in Pediatric Extracorporeal Membrane Oxygenation
Transplantation of Autologously Derived Mitochondria Following Ischemia
Evaluating the Safety and Performance of the MiniLung Petite Kit in Neonatal and Pediatric Patients With Acute Respiratory and Cardiac Failure
Continuous Compartment Pressure Monitoring for Compartment Syndrome in VA-ECMO Patients
Impact of ECMO Cannula Chlorhexidine-impregnated Dressings to Decrease Extracorporeal Membrane Oxygenation-cannula Related Infection Rate
Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO
Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation
ECMO ABI Detection With Hyperfine
DIC Markers and Thrombin Generation Parameters in Patients on ECMO Support: a Pilot Study
EUROSETS ECMO Study in Clinical Extracorporeal Life Support Applications
ECMO Hemostatic Transfusions in Children
Red Blood Cell Transfusion in ECMO - A Feasibility Trial
RECOMMEND Platform Trial
LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients